Projects
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB). University of Antwerp
String test: a new tool to improve the diagnosis of tuberculosis and the detection of drug resistance in children Ghent University
The aim of this research project is to improve the diagnosis of tuberculosis (TB) in children
and to potentially advance the detection of drug resistance from one simplified clinical sampling.
The string test proposes a new technique to obtain the same clinical sample which is the gastric
content. The specific objectives of the study are to explore the potential of using a new tool: the
"string test" ...
Multi Omics Data Integration to predict the M. tuberculosis Bedaquiline Resistance Phenotype from the Genotype Institute of Tropical Medicine
Currently, clinical research on the best combinations in which to use new drugs suffers from a genotype-phenotype gap: we can test for resistance in the lab (phenotype) but we can’t predict the phenotype from
mutations. Resistance testing for Bedaquiline is ...
Synthesis and biological assessment of novel β-lactamase inhibitors in the framework of tuberculosis therapy in India Ghent University
Tuberculosis (TB) is an infectious disease responsible for 220.000 deaths per year in India, imposing an immense burden on the country’s health care system. This project aims at establishing an innovative approach in anti-TB therapy by designing β-lactamase inhibitors that could allow classical
β-lactam antibiotics to exert their antibacterial action against (resistant) Mycobacterium tuberculosis strains.
Utilization of molecular resistance test results as tools to support public health efforts for improved control of rifampicin resistant tuberculosis Institute of Tropical Medicine
Development of a two-approach plate system for the fast and simultaneous detection of MDR and XDR M. tuberculosis Institute of Tropical Medicine
Tuberculosis (TB) continues being a leading cause of death due to a single infectious disease agent. The HIV/AIDS pandemic and the emergence of drug resistance are compounding factors that hinder the control of the disease. Associated with this problem is the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, defined as strains resistant to at least isoniazid and rifampicin, the most valuable drugs in the treatment ...